BackOncoTherapy Science Overview

OncoTherapy Science Receivables

OncoTherapy Science's receivables is $82M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$82.45M
↑ 83.36% YoYΔ $37.48M vs prior year quarter

Peer trimmed avg / median

Loading

OncoTherapy Science Receivables History

Loading

OncoTherapy Science vs. peers: Receivables Comparison

Loading

OncoTherapy Science Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

OncoTherapy Science (4564.T) FAQ

The latest receivables for 4564.T is $82M as of September 2026. That compares with $45M in the prior-year period — up 83.4% year over year. Investors often review this figure alongside OncoTherapy Science's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4564.T's receivables moved from $45M to $82M — a 83.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in OncoTherapy Science's operating scale or balance-sheet position.

A receivables figure of $82M for 4564.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4564.T's receivables ($82M), review year-over-year change from $45M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack OncoTherapy Science's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.